Johnson & Johnson Reaches $5.5 Billion Talc Settlement Amid Long-Running Litigation
After years of legal battles, Johnson & Johnson has reached a proposed settlement worth at least $5.5 billion to resolve thousands of lawsuits alleging its talc-based products caused ovarian cancer. The litigation, which spans over a decade and involves tens of thousands of plaintiffs, has resulted in mixed court outcomes for the company. J&J previously attempted three bankruptcy-related settlements that were rejected by courts due to opposition from some plaintiff lawyers. The new settlement differs significantly from past attempts as it is voluntary and does not require future claimants or non-consenting parties to be bound by its terms. It also promises faster payouts—within two years, compared to a potential 25-year timeline under previous bankruptcy proposals. The deal must gain acceptance from at least 95% of the estimated 76,000 ovarian cancer claims to proceed. While J&J and major plaintiffs' law firms have expressed optimism about the settlement's success, some plaintiff lawyers are still reviewing its terms. A recent court ruling may also influence more claimants to accept the deal by casting doubt on their ability to prove future cases in light of stricter scientific evidence standards.
Tickers: $JNJ
Topics: Johnson & Johnson lawsuits ovarian cancer claims talc litigation